Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ralf A Linker

Showing results (1-10 of 201) with videos related to

Pageof 21
Sort By:
Therapeutic Advances in Chronic Disease|July 20, 2016
Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapyRalf A Linker, Aiden Haghikia
Drug Design, Development and Therapy|April 5, 2016
Laquinimod in the treatment of multiple sclerosis: a review of the data so farJan Thöne, Ralf A Linker
Journal of Neuroimmunology|October 17, 2008
Remote changes in gene expression after autoimmune demyelination: grey mattersRalf A Linker, Ralf Gold
Neurology and Therapy|September 15, 2016
Cardiac Safety Profile of First Dose of Fingolimod for Relapsing-Remitting Multiple Sclerosis in Real-World Settings: Data from a German Prospective Multi-Center Observational StudyRalf A Linker, Guillaume Wendt
Journal of Immunology (Baltimore, Md. : 1950)|August 24, 2004
MBP-induced experimental autoimmune encephalomyelitis in C57BL/6 miceRalf A Linker, Ralf Gold
Current Neurology and Neuroscience Reports|September 25, 2013
Dimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side effectsRalf A Linker, Ralf Gold
Neurological Research and Practice|December 16, 2020
Navigating choice in multiple sclerosis managementRalf A Linker, Andrew Chan
Current Opinion in Neurology|May 3, 2008
Use of intravenous immunoglobulin and plasma exchange in neurological diseaseRalf A Linker, Ralf Gold
Expert Review of Clinical Pharmacology|August 10, 2013
Dimethyl fumarate (BG-12) for the treatment of multiple sclerosisMartin Stangel, Ralf A Linker
Therapeutic Advances in Neurological Disorders|May 5, 2021
Inflammation in multiple sclerosisStefanie Haase, Ralf A Linker
Pageof 21

Showing results (1-10 of 201) with videos related to

Sort By:
Pageof 21
Therapeutic Advances in Chronic Disease|July 20, 2016
Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapyRalf A Linker, Aiden Haghikia
Drug Design, Development and Therapy|April 5, 2016
Laquinimod in the treatment of multiple sclerosis: a review of the data so farJan Thöne, Ralf A Linker
Journal of Neuroimmunology|October 17, 2008
Remote changes in gene expression after autoimmune demyelination: grey mattersRalf A Linker, Ralf Gold
Neurology and Therapy|September 15, 2016
Cardiac Safety Profile of First Dose of Fingolimod for Relapsing-Remitting Multiple Sclerosis in Real-World Settings: Data from a German Prospective Multi-Center Observational StudyRalf A Linker, Guillaume Wendt
Journal of Immunology (Baltimore, Md. : 1950)|August 24, 2004
MBP-induced experimental autoimmune encephalomyelitis in C57BL/6 miceRalf A Linker, Ralf Gold
Current Neurology and Neuroscience Reports|September 25, 2013
Dimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side effectsRalf A Linker, Ralf Gold
Neurological Research and Practice|December 16, 2020
Navigating choice in multiple sclerosis managementRalf A Linker, Andrew Chan
Current Opinion in Neurology|May 3, 2008
Use of intravenous immunoglobulin and plasma exchange in neurological diseaseRalf A Linker, Ralf Gold
Expert Review of Clinical Pharmacology|August 10, 2013
Dimethyl fumarate (BG-12) for the treatment of multiple sclerosisMartin Stangel, Ralf A Linker
Therapeutic Advances in Neurological Disorders|May 5, 2021
Inflammation in multiple sclerosisStefanie Haase, Ralf A Linker
Pageof 21